Refine
Year of publication
- 2011 (189) (remove)
Institute
- Fachbereich Medizintechnik und Technomathematik (71)
- INB - Institut für Nano- und Biotechnologien (35)
- Fachbereich Elektrotechnik und Informationstechnik (31)
- IfB - Institut für Bioengineering (29)
- Fachbereich Chemie und Biotechnologie (22)
- Fachbereich Luft- und Raumfahrttechnik (16)
- Fachbereich Energietechnik (15)
- Fachbereich Maschinenbau und Mechatronik (12)
- Solar-Institut Jülich (11)
- Fachbereich Bauingenieurwesen (5)
Language
- English (189) (remove)
Document Type
- Article (130)
- Conference Proceeding (44)
- Part of a Book (8)
- Conference: Meeting Abstract (3)
- Book (2)
- Doctoral Thesis (2)
Keywords
- Pflanzenphysiologie (2)
- Pflanzenscanner (2)
- plant scanner (2)
- Aktionskunst (1)
- Anastomose (1)
- Anastomosis (1)
- Biomechanics (1)
- Biomechanik (1)
- Bioreaktor (1)
- Blutzellenlagerung (1)
The contribution of altered post-transcriptional gene silencing to the development of insulin resistance and type 2 diabetes mellitus so far remains elusive. Here, we demonstrate that expression of microRNA (miR)-143 and 145 is upregulated in the liver of genetic and dietary mouse models of obesity. Induced transgenic overexpression of miR-143, but not miR-145, impairs insulin-stimulated AKT activation and glucose homeostasis. Conversely, mice deficient for the miR-143–145 cluster are protected from the development of obesity-associated insulin resistance. Quantitative-mass-spectrometry-based analysis of hepatic protein expression in miR-143-overexpressing mice revealed miR-143-dependent downregulation of oxysterol-binding-protein-related protein (ORP) 8. Reduced ORP8 expression in cultured liver cells impairs the ability of insulin to induce AKT activation, revealing an ORP8-dependent mechanism of AKT regulation. Our experiments provide direct evidence that dysregulated post-transcriptional gene silencing contributes to the development of obesity-induced insulin resistance, and characterize the miR-143–ORP8 pathway as a potential target for the treatment of obesity-associated diabetes.